Document is current
Any future updates will be listed below
-
Authors
Hornbecker, Michael
Suchsland, Monica Zigman
MacLeod, Tim
Koppenhofer, Mary Jo
Selzler, Katherine J.
Ferrell, Phyllis
Deckert, Amy
- License Information
-
More Information
Article History
Received: 20 December 2024
Accepted: 6 April 2026
First Online: 28 April 2026
Declarations
:
: This study is being conducted in accordance with the Declaration of Helsinki and will adhere to Good Clinical Practice guidelines. Ethics approval for this ongoing study was obtained from the Advarra Institutional Review Board, Columbia, Maryland, United States (#Pro00081688; Continuing Review Approval CR00696943). The IRB approved a Waiver of Documentation of Informed Consent for this ongoing study.
: Not applicable. This manuscript reports on methodology only and does not contain any individual participant data.
: MH has served as a consultant for Eisai, Novo Nordisk, and Neurotrack Technologies and is a minor shareholder of Eli Lilly and Company.MJK and KJS are minor shareholders of Eli Lilly and Company.PF provides advising services for Gates Ventures, the Alzheimer’s Drug Discovery Foundation, and Morningside Technology Advisory and StartUp Health and their portfolio companies and is a minor shareholder of Eli Lilly and Company.All authors receive consulting fees from the Davos Alzheimer’s Collaborative.
